1. Market Research
  2. > Pharmaceutical
  3. > Biopharmaceutical Market Trends
Immunotherapy Drugs Market by Type, Therapy Area, End User - Global Forecast to 2025

Immunotherapy Drugs Market by Type, Therapy Area, End User - Global Forecast to 2025

  • May 2020
  • 177 pages
  • ID: 4605996
  • Format: PDF
  • MarketsandMarkets


Table of Contents

Search Inside

The immunotherapy drugs market is projected to grow at a CAGR of 11.0% during the forecast period (2020–2025).
The global immunotherapy drugs market is projected to reach USD 274.6 billion by 2025 from USD 163.0 billion in 2020, at a CAGR of 11.0 % during the forecast period. Market growth is primarily driven by the rising demand for immunotherapies over conventional treatments and a growing prevalence of target indications. However, timeline issues, side-effects, and manufacturing complexities are expected to restrict market growth to a certain extent.

Monoclonal antibodies are expected to witness high demand during the forecast period.
The adoption of immunotherapy in cancer has been rising in recent years due to the introduction of safe and efficient treatments.Monoclonal antibodies are immunoglobulins derived by cultivating immune cells in the lab to target specific antigens present on the surface of cancer cells.

These antibodies, when used as a therapy, attach themselves to cancer/abnormal cells and mark them for destruction by the body’s natural immune system. Monoclonal antibodies hold the largest share of the immunotherapy drugs market owing to their high specificity and few side-effects.

Cancer is one of the key application areas for immunotherapies.
On the basis of the therapeutic area, the immunotherapy drugs market is segmented into cancer, autoimmune & inflammatory diseases, infectious diseases, and others.Cancer accounted for the largest share of the immunotherapy drugs market in 2019.

This is mainly due to the large number of approvals, rising prevalence of cancer, and growing research activity in this area, among other factors.
• By end user, hospitals accounted for the largest share of the immunotherapy drugs market in 2019.

On the basis of the end user, the global immunotherapy drugs market is segmented into hospitals, clinics, and other end users. Hospitals accounted for the largest share of the immunotherapy drugs market in 2019, mainly due to their high spending on immunotherapies and the availability of the necessary infrastructure and facilities to provide advanced treatments.

The market in North America is projected to hold the largest share of the global immunotherapy drugs market.
North America is projected to dominate the market during the forecast period.This can be attributed to factors such as the rising prevalence of cancer and increasing initiatives by industry players.

On the other hand, the Asia Pacific region is expected to grow at the highest CAGR of 11.9% during the forecast period due to factors such as aggressive investments by key market players and the increase in government spending on healthcare.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type (Supply-side): Tier 1: 29%, Tier 2: 37%, and Tier 3: 34%
• By Category (Demand-side): Pharmaceutical & Biotechnology Companies: 55%, Hospitals and Reference Laboratories: 35%, and Academic & Research Institutes: 10%
• By Designation: C-level: 35%, Director level: 25%, and Managers: 40%
• By Region: North America: 35%, Europe: 32%, Asia: 22%, and the RoW: 11%

F. Hoffmann-La Roche Ltd. (UK), Pfizer Inc. (US), and Merck & Co (US) are the key players operating in the immunotherapy drugs market. Others include Novartis International AG (UK), Johnson & Johnson (US), Sanofi (France), GlaxoSmithKline Plc (UK), Amgen Inc. (US), AbbVie Inc. (US), Boehringer Ingelheim (Germany), AstraZeneca (UK), and Immatics Biotechnologies (Germany).

Research Coverage:
The report analyzes the immunotherapy drugs market and aims at estimating the market size and future growth potential of this market based on various segments such as product, type, application, end user, and region. The report also includes competitive analyses of the key players in this market, along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the immunotherapy drugs market. The report analyzes the market based on type, therapeutic area, end user, and region
• Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the immunotherapy drugs market
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of immunotherapy drugs solutions across regions
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the immunotherapy drugs market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the immunotherapy drugs market

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Immunotherapy Drugs 2016-2020

  • $ 2500
  • March 2016
  • 159 pages

About Immunotherapy Drugs Immunotherapy enhances the innate powers of the immune system. The properties of the immune system to fight abnormal cells give immunotherapy drugs the chance of successfully ...

  • United States
  • World
  • Therapy
  • Immunotherapy
  • Industry analysis
  • Drug Approval
  • Cancer Incidence


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on